Aceto-whitening in the Assessment of Gastrointestinal Neoplasia
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Acetic acid chromoendoscopy is an established standard technique used to detect dysplasia within the gastrointestinal tract. Acetic acid spray helps to identify neoplasia by highlighting the surface pattern, highlighting the vascular pattern and by a process known as the aceto-whitening reaction, where tissues take acetic acid and turn white for a brief period and then slowly revert back to a normal colour. The neoplastic surface and vascular pattern are all very well described, and have played a big role in the recognition of early cancer. The aceto-whitening reaction is well described but the differential in timing between neoplastic and non-neoplastic areas is not well understood.
The investigators aim to establish the differential in the timing of the disappearance of the aceto-whitening reaction between healthy tissue, dysplastic tissue, intramucosal cancer and invasive cancer after acetic acid dye spray in the oesophagus and colon. By understanding this better, the investigators may be able to predict with greater accuracy whether a highlighted abnormal area is cancer or high grade dysplasia, or whether it is low grade dysplasia or inflammation, which has significant prognostic implications for the patient.
The investigators hypothesize that the differential in the timing of the disappearance of the aceto-whitening reaction between normal and abnormal tissue could help in the detection of gastrointestinal neoplasia.
| Condition | Intervention |
|---|---|
|
Barrett Esophagus Barrett Metaplasia Barrett Oesophagitis With Dysplasia Barrett Adenocarcinoma |
Procedure: Acetic acid chromoendoscopy |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Acetowhitening Time as a Novel Objective Tool for the Diagnosis of High Risk Neoplasia in Barrett's Oesophagus |
- Timing of disappearance of aceto-whitening for Barrett's metaplasia, HGD and cancer [ Time Frame: 18 months ] [ Designated as safety issue: No ]To quantify the differential in the timing of the disappearance of the aceto-whitening reaction between metaplastic tissue, dysplastic tissue and invasive cancer after acetic acid dye spray in the oesophagus and colon.
- To differentiate mucosal neoplasia from invasive cancer [ Time Frame: 24 months ] [ Designated as safety issue: No ]To differentiate high grade displasia and intramucosal cancer from invasive cancer using the aceto-whitening timing
Biospecimen Retention: None Retained
Only pathology retained is for NHS purposes only. No separate tissue retained for the study
| Estimated Enrollment: | 150 |
| Study Start Date: | November 2010 |
| Estimated Study Completion Date: | November 2013 |
| Primary Completion Date: | September 2011 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
Acetic acid chromoendoscopy
|
Procedure: Acetic acid chromoendoscopy
Prospective observational pilot study. We would examine patients with Barrett's epithelium that is either healthy or has suspected areas of neoplasia. We will apply acetic acid spray to areas of healthy Barrett's metaplasia and time how long it takes for the aceto whitening to disappear. We will repeat this in cases referred with SM invasive cancer, intramucosal cancer, suspected high grade dysplasia and possible low grade dysplasia. We will record how long it takes for the acetowhitening to disappear. We will biopsy these areas to confirm the diagnosis. We will correlate the histology to the aceto-whitening time to see if there is a correlation between the degree of neoplasia and the aceto-whitening time after acetic acid dye spray. |
Detailed Description:
This is a prospective pilot study. It is standard practice within our unit to use acetic acid for the detection of neoplasia. No patient would receive any additional intervention that would not normally be performed.
We will record the surface and vascular patterns before and after acetic acid spray. As usual we will then apply acetic acid spray to the Barrett's epithelium and time how long it takes for the aceto whitening to disappear. It is the timing of the disappearance that is the key study intervention. We will biopsy these areas to confirm the diagnosis. Again this is standard practice and no patient will be denied an intervention that is normally performed, and no extra interventions will be performed over and above the standard clinical practice.
We will correlate the histology to the aceto-whitening disappearance time to identify a threshold time which can serve as a cut off between neoplastic and non-neoplastic tissue.
We hypothesise that the aceto-whitening reaction lasts much longer in the normal epithelium of Barrett's oesophagus and colon. This reaction will be much shorter in areas with abnormal pathology like dysplasia or cancer.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Patients undergoing surveillance for Barrett's oesophagus
Inclusion Criteria:
- Patients with known Barrett's metaplasia under surveillance
- Patients with Barrett's metaplasia who had undergone endoscopic treatment for neoplasia previously and were under surveillance for metachronous neoplasia
- Patients suspected of neoplasia referred for endoscopic mucosal resection or other targeted endoscopic treatment of the lesion
Exclusion Criteria:
- Oesophagitis
- Contact bleeding
- Acute mucosal trauma
Contacts and Locations| United Kingdom | |
| Portsmouth Hospitals NHS trust | Recruiting |
| Portsmouth, Hampshire, United Kingdom, PO76TS | |
| Contact: Gaius Longcroft-Wheaton, MD, MRCP +442392252913 gaius@gaius.wanadoo.co.uk | |
| Contact: Pradeep Bhandari, MD, FRCP 02392286000 deep3570@yahoo.co.uk | |
| Principal Investigator: Pradeep Bhandari, MD, FRCP | |
| Sub-Investigator: Gaius Longcroft-Wheaton, MD, MRCP | |
| Principal Investigator: | Pradeep Bhandari, MD, FRCP | Portsmouth Hospitals NHS Trust |
More Information
No publications provided
| Responsible Party: | Pradeep Bhandari, Consultant Gastroenterologist, Portsmouth Hospitals NHS Trust |
| ClinicalTrials.gov Identifier: | NCT01618643 History of Changes |
| Other Study ID Numbers: | PHT/2010/25 |
| Study First Received: | June 11, 2012 |
| Last Updated: | June 13, 2012 |
| Health Authority: | United Kingdom: Research Ethics Committee |
Keywords provided by Portsmouth Hospitals NHS Trust:
|
Barrett's High grade dysplasia HGD IMC |
Intramucosal cancer Acetic acid Chromoendoscopy |
Additional relevant MeSH terms:
|
Adenocarcinoma Adenocarcinoma, Mucinous Barrett Esophagus Neoplasms Esophagitis Metaplasia Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms, Cystic, Mucinous, and Serous Digestive System Abnormalities Digestive System Diseases Esophageal Diseases |
Gastrointestinal Diseases Gastroenteritis Pathologic Processes Retinol acetate Adjuvants, Immunologic Immunologic Factors Physiological Effects of Drugs Pharmacologic Actions Anticarcinogenic Agents Protective Agents Antineoplastic Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 23, 2013